DNA damage response-related proteins in gastric cancer: ATM, Chk2 and p53 expression and their prognostic value

Pathobiology

Volumn 81, Issue 1, 2013, Pages 25-35

  Lee, Hee Eun ^a,b   Han, Nayoung ^a,b   Kim, Min A ^a,b   Lee, Hye Seung ^b,c   Yang, Han Kwang ^b   Lee, Byung Lan ^b   Kim, Woo Ho ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Ataxia telangiectasia mutated protein; Checkpoint kinase 2; DNA damage response; Immunohistochemistry; Stomach neoplasm; Survival analysis; Tumor suppressor protein p53

Indexed keywords

ATM PROTEIN; BIOLOGICAL MARKER; CHECKPOINT KINASE 2; KI 67 ANTIGEN; PROTEIN P53;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR INVASION; CANCER PATIENT; CANCER SURGERY; DNA DAMAGE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSTIC ASSESSMENT; PROTEIN DEPLETION; VALIDATION STUDY;

ADENOCARCINOMA; ADULT; AGED; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CHECKPOINT KINASE 2; DNA DAMAGE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84887113789     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000351072     Document Type: Article

References (29)

1. American Joint Committee on Cancer: Chapter 11: stomach; in Edge SB, Byrd DR, Campton CC, Fritz AG, Greene FL, Trotti A (eds): AJCC Cancer Staging Manual, ed 7. New York, Springer, 2009, pp 117-126.
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
3. Hartgrink HH, van de Velde CJ: Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer. J Surg Oncol 2005; 90: 153-165. (Pubitemid 40741180)
4. Hejna M, Wohrer S, Schmidinger M, Raderer M: Postoperative chemotherapy for gastric cancer. Oncologist 2006; 11: 136-145. (Pubitemid 43261760)
5. Novotny AR, Schuhmacher C, Busch R, Kattan MW, Brennan MF, Siewert JR: Predicting individual survival after gastric cancer resection: validation of a US-derived nomogram at a single high-volume center in Europe. Ann Surg 2006; 243: 74-81. (Pubitemid 43054057)
6. Ichikura T, Tomimatsu S, Uefuji K, Kimura M, Uchida T, Morita D, Mochizuki H: Evaluation of the New American Joint Committee on Cancer/International Union against Cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification. Cancer 1999; 86: 553-558. (Pubitemid 29379399)
7. Hartwell LH, Weinert TA: Checkpoints: controls that ensure the order of cell cycle events. Science 1989; 246: 629-634. (Pubitemid 19283354)
8. Kastan MB, Bartek J: Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-323. (Pubitemid 39551659)
9. Kim HS, Kim MA, Hodgson D, Harbron C, Wellings R, O'Connor MJ, Womack C, Yin X, Bang YJ, Im SA, Lee BL, Kim WH: Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients. Pathobiology 2013; 80: 127-137.
10. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331. (Pubitemid 27131374)
11. Schipper DL, Wagenmans MJ, Peters WH, Wagener DJ: Significance of cell proliferation measurement in gastric cancer. Eur J Cancer 1998; 34: 781-790. (Pubitemid 28248486)
12. Lee HE, Kim MA, Lee BL, Kim WH: Low Ki- 67 proliferation index is an indicator of poor prognosis in gastric cancer. J Surg Oncol 2010; 102: 201-206.
13. Lee HS, Lee HK, Kim HS, Yang HK, Kim YI, Kim WH: MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer 2001; 92: 1427-1434. (Pubitemid 32947826)
14. Park JH, Lee BL, Yoon J, Kim J, Kim MA, Yang HK, Kim WH: Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum Pathol 2010; 41: 1664-1673.
15. Zhou BB, Bartek J: Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4: 216-225. (Pubitemid 38337501)
16. Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA: Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 2012; 32: 1661-1672.
17. Begnami MD, Fregnani JH, Nonogaki S, Soares FA: Evaluation of cell cycle protein expression in gastric cancer: cyclin B1 expression and its prognostic implication. Hum Pathol 2010; 41: 1120-1127.
18. Grabsch H, Dattani M, Barker L, Maughan N, Maude K, Hansen O, Gabbert HE, Quirke P, Mueller W: Expression of DNA doublestrand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. Clin Cancer Res 2006; 12: 1494-1500.
19. Hashiguchi Y, Tsuda H, Inoue T, Nishimura S, Suzuki T, Kawamura N: Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum Pathol 2004; 35: 165-175. (Pubitemid 38240898)
20. Sarbia M, Ott N, Puhringer-Oppermann F, Brucher BL: The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br J Cancer 2007; 97: 1404-1408. (Pubitemid 350114789)
21. Kang B, Guo RF, Tan XH, Zhao M, Tang ZB, Lu YY: Expression status of ataxia-telangiectasia- mutated gene correlated with prognosis in advanced gastric cancer. Mutat Res 2008; 638: 17-25.
22. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238. (Pubitemid 120031831)
23. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747- 749. (Pubitemid 120015153)
24. Wu X, Webster SR, Chen J: Characterization of tumor-associated Chk2 mutations. J Biol Chem 2001; 276: 2971-2974.
25. Zhang L, Jia G, Li WM, Guo RF, Cui JT, Yang L, Lu YY: Alteration of the ATM gene occurs in gastric cancer cell lines and primary tumors associated with cellular response to DNA damage. Mutat Res 2004; 557: 41-51. (Pubitemid 38045580)
26. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991; 253: 49-53. (Pubitemid 21917115)
27. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
28. Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T: The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010; 116: 4578-4587.
29. Williamson CT, Muzik H, Turhan AG, Zamo A, O'Connor MJ, Bebb DG, Lees-Miller SP: ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010; 9: 347-357.